Access cutting-edge heparin induced thrombocytopenia treatment through this clinical trial at a research site in New Haven. Study-provided care at no cost to qualified participants.
Access heparin induced thrombocytopenia specialists in New Haven at no cost
This study follows strict safety protocols and ethical guidelines
All study-related heparin induced thrombocytopenia treatment provided free
The purpose of this study is to evaluate the efficacy and safety of VLX-1005, a 12-lipoxygenase (12-LOX) enzyme inhibitor in treating heparin induced thrombocytopenia (HIT). Participants with suspected HIT will receive the usual standard of care, and will be assigned randomly to either VLX-1005 or placebo treatment. The study will measure important outcomes including platelet count, stroke, pulmonary embolus (clot to the lungs) and bleeding.
Sponsor: Veralox Therapeutics
Check if you qualify for this heparin induced thrombocytopenia clinical trial in New Haven, CT
If you're searching for heparin induced thrombocytopenia treatment options in New Haven, CT, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our New Haven research site is actively enrolling participants for this clinical trial. You'll receive care from experienced heparin induced thrombocytopenia specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.